Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even ...

McALLEN, Texas (AP) — A 27-year-old man was killed Monday after opening fire at a U.S. Border Patrol facility in McAllen, Texas, authorities said. Federal agents returned fire at Ryan Louis Mosqueda, ...

In the Hill Country area, home to Camp Mystic and several other summer camps, searchers have found the bodies of 75 people, ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a ...

THE WHAT? A U.S. federal judge has upheld the FDA’s decision to remove semaglutide, the active ingredient in Ozempic and Wegovy, from the drug shortage list—blocking compounding pharmacies from ...

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).

-A federal judge in Texas has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's blockbuster drugs Ozempic and Wegovy, upholding the U.S. Food and ...